Literature DB >> 9870315

A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes.

M Lagranderie1, N Winter, A M Balazuc, B Gicquel, M Gheorghiu.   

Abstract

Recombinant live Mycobacterium bovis BCG strains (rBCG) expressing different human immunodeficiency virus (HIV) or simian immunodeficiency (SIV) antigens could be good candidates for the development of vaccines against AIDS. To develop effective HIV/SIV vaccines, humoral and cellular immune responses directed against multiple antigens may be essential for the control of the infection. In this study we immunized BALB/c mice via different mucosal routes (oral, aerogenic, nasal, and rectal) with a mixture of three rBCG strains expressing, respectively, the entire SIVmac251 Nef protein, and large fragments of the Env and Gag proteins. All routes of immunization studied induced immunoglobulin A (IgA) antibodies against mycobacterial PPD, SIV Env, and SIV Gag antigens in feces and bronchial lavages as well as specific immunoglobulin G (IgG) in serum. Strong, specific cytotoxic responses of splenocytes against Nef, Env, and Gag was observed whatever the mucosal route of immunization. Therefore, mucosal vaccination with a cocktail of rBCG strains induces local, specific IgA, systemic IgG, and systemic CTLs against the three SIV antigens expressed. Rectal and oral routes seemed the most appropriate route of vaccination to be used to protect against SIV infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870315     DOI: 10.1089/aid.1998.14.1625

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

1.  Plasmidic versus insertional cloning of heterologous genes in Mycobacterium bovis BCG: impact on in vivo antigen persistence and immune responses.

Authors:  I Méderlé; I Bourguin; D Ensergueix; E Badell; J Moniz-Peireira; B Gicquel; N Winter
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

2.  Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus.

Authors:  Sang-Moo Kang; Richard W Compans
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B.

Authors:  Sang-Moo Kang; Qizhi Yao; Lizheng Guo; Richard W Compans
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 4.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

5.  Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

Authors:  V Novitsky; H Cao; N Rybak; P Gilbert; M F McLane; S Gaolekwe; T Peter; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

6.  Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis.

Authors:  Lihao Chen; Jun Wang; Anna Zganiacz; Zhou Xing
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.

Authors:  Sang-Moo Kang; Lizheng Guo; Qizhi Yao; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 8.  Enhancing oral vaccine potency by targeting intestinal M cells.

Authors:  Ali Azizi; Ashok Kumar; Francisco Diaz-Mitoma; Jiri Mestecky
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

9.  Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes.

Authors:  Narcís Saubi; Eung-Jun Im; Raquel Fernández-Lloris; Olga Gil; Pere-Joan Cardona; Josep Maria Gatell; Tomáš Hanke; Joan Joseph
Journal:  Clin Dev Immunol       Date:  2011-04-12

10.  Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells.

Authors:  Manjunatha M Venkataswamy; Tony W Ng; Shalu S Kharkwal; Leandro J Carreño; Alison J Johnson; Shajo Kunnath-Velayudhan; Zheng Liu; Robert Bittman; Peter J Jervis; Liam R Cox; Gurdyal S Besra; Xiangshu Wen; Weiming Yuan; Moriya Tsuji; Xiangming Li; David D Ho; John Chan; Sunhee Lee; Richard Frothingham; Barton F Haynes; Michael W Panas; Geoffrey O Gillard; Jaimie D Sixsmith; Birgit Korioth-Schmitz; Joern E Schmitz; Michelle H Larsen; William R Jacobs; Steven A Porcelli
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.